文献速递乳腺癌头颈与中枢神经肿瘤

乳腺癌脑转移基因组全景:系统综述

The genomic landscape of breast cancer brain metastases: a systematic review.
PubMed 文献 · Lancet Oncol · 2021-01-01

本系统综述检索PubMed、Embase和Scopus截至2020年5月30日的英文文献,纳入13项乳腺癌脑转移测序研究、共164例患者的脑转移样本。分析识别出268个在至少2个样本中突变的基因,其中22个在5例及以上患者中突变,15个为可靶向药物靶点,并发现原发灶与脑转移灶间受体状态不一致。

要点

  • 乳腺癌脑转移基因组与原发灶不同,存在原发灶缺失的突变。
  • 164例脑转移样本中识别268个突变基因,22个在≥5例患者中突变。
  • 22个高频突变基因中15个为可靶向药物靶点,涉及DNA修复等通路。

核心结论

  • 乳腺癌脑转移具有与原发肿瘤不同的基因组景观,强调获取和分析脑转移样本的重要性。

研究设计与样本

  • 系统综述,检索PubMed、Embase和Scopus截至2020年5月30日的英文文献。
  • 从431篇文献中纳入13项测序研究,共164例患者的脑转移样本。

主要发现

  • 识别出268个在至少2个乳腺癌脑转移样本中突变的基因。
  • 268个基因中22个在5例及以上患者中突变,通路富集分析显示参与乳腺癌相关信号通路、基因转录调控、细胞周期和DNA修复。
  • 22个基因中15个(68%)为可靶向药物靶点。
  • 免疫组化和PAM50数据显示原发乳腺癌与配对脑转移灶间存在受体状态不一致。

关键数值与推荐

  • 268个突变基因中22个(8%)在5例及以上患者中突变。
  • 22个高频突变基因中15个(68%)为可靶向药物靶点。

临床怎么用

  • 提示临床应重视脑转移灶活检和基因组分析,以指导靶向治疗选择。
  • 原发灶与脑转移灶受体状态可能不一致,需重新评估脑转移灶受体状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Breast cancer brain metastases are an increasing clinical problem. Studies have shown that brain metastases from breast cancer have a distinct genomic landscape to that of the primary tumour, including the presence of mutations that are absent in the primary breast tumour. In this Review, we aim to review and evaluate genomic sequencing data for breast cancer brain metastases by searching PubMed, Embase, and Scopus for relevant articles published in English between database inception and May 30, 2020. Extracted information includes data for mutations, receptor status (eg, immunohistochemistry and Prediction Analysis of Microarray 50 [PAM50]), and copy number alterations from published manuscripts and supplementary materials. Of the 431 articles returned by the database search, 13 (3%) breast cancer brain metastases sequencing studies, comprising 164 patients with sequenced brain metastases, met all our inclusion criteria. We identified 268 mutated genes that were present in two or more breast cancer brain metastases samples. Of these 268 genes, 22 (8%) were mutated in five or more patients and pathway enrichment analysis showed their involvement in breast cancer-related signalling pathways, regulation of gene transcription, cell cycle, and DNA repair. Actionability analysis using the Drug Gene Interaction Database revealed that 15 (68%) of these 22 genes are actionable drug targets. In addition, immunohistochemistry and PAM50 data showed receptor discordancy between primary breast cancers and their paired brain metastases. This systematic review provides a detailed overview of the most commonly mutated genes identified in samples of breast cancer brain metastases and their clinical relevance. These data highlight the differences between primary breast cancers and brain metastases and the importance of acquiring and analysing brain metastasis samples for further study.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Morgan AJ, Giannoudis A, Palmieri C, et al. The genomic landscape of breast cancer brain metastases: a systematic review. Lancet Oncol. 2021. PMID: 33387511. doi:10.1016/S1470-2045(20)30556-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。